Embecta Corp. (EMBC) vs Relmada Therapeutics, Inc. (RLMD)

A side-by-side comparison of Embecta Corp. and Relmada Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Embecta Corp. logo
EMBC
Embecta Corp.
$357M
$6.02HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
Relmada Therapeutics, Inc. logo
RLMD
Relmada Therapeutics, Inc.
$348M
$3.32HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT

Total return — EMBC vs RLMD

growth of $100 · dividends reinvested · last 5y
EMBC -85.5% (-32.1%/yr)RLMD -25.5% (-5.7%/yr)RLMD compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $1002023202420252026$14$75
EMBC RLMD

EMBC vs RLMD: by the numbers

  • •EMBC is the larger company ($357M vs $348M market cap).
  • •EMBC is profitable (8.59% net margin) while RLMD runs a net loss (0.00%).
  • •EMBC pays a dividend (5.44% yield), while RLMD has no payments in the available dividend history.

Metrics side by side

Valuation

MetricEMBCRLMD
P/E ratio4.07N/A
Forward P/E3.42N/A
P/S ratio0.35N/A
P/B ratioN/A1.68
EV / EBITDA5.39N/A
FCF yield46.07%N/A

Profitability

MetricEMBCRLMD
Gross margin59.89%0.00%
Operating margin24.85%0.00%
Net margin8.59%0.00%
ROEN/A-29.98%
ROIC17.99%-30.78%

Dividends

MetricEMBCRLMD
Dividend yield5.44%N/A
Payout ratio21.62%N/A

Growth (annualized)

MetricEMBCRLMD
Revenue CAGR (5Y)-0.09%N/A
EPS CAGR (5Y)-26.22%N/A
FCF CAGR (5Y)-16.77%N/A
Total return CAGR (5Y)N/A-7.68%

Frequently asked

Does EMBC or RLMD pay a bigger dividend?
EMBC pays a dividend (5.44% yield), while RLMD has no payments in the available dividend history.
Is EMBC or RLMD more profitable?
EMBC runs the higher net margin — EMBC at 8.59% versus RLMD at 0.00%.

Go deeper

Full EMBC analysisFull RLMD analysisInteractive comparison tool

Dig into the metrics

Embecta P/E ratioEmbecta dividend yieldEmbecta ROERelmada Therapeutics ROEEmbecta operating marginRelmada Therapeutics operating marginEmbecta revenue growthRelmada Therapeutics revenue growthEmbecta free cash flowRelmada Therapeutics free cash flow

Embecta & Relmada Therapeutics appear in these rankings

Highest Dividend Yield StocksHighest FCF Yield StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.